Intelligent Product Solutions Selected for New York Product Design Award for Its Work on the EON Laser
IPS wins New York Product Design Award for its design work on the EON Laser, a fat reduction device by Dominion Aesthetic Technologies
HAUPPAUGE, N.Y., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Product Solutions (IPS) today announced that it received a New York Product Design award, for its product design work on the EON Laser, a FDA-cleared, touch-free, and pain-free fat reduction device by Dominion Aesthetic Technologies. A global product design and development firm, Intelligent Product Solutions is a subsidiary of Forward Industries (NASDAQ: FORD).
The New York Product Design awards honor the efforts of talented product designers, design teams and manufacturers from all over the world. It recognizes the contributions they have made to daily living, with their practical and ingenious creations.
'At IPS, we're proud to receive this award for our innovative medical device design of this revolutionary product,' said Bob Wild, CEO of Intelligent Product Solutions. 'Working with Dominion Aesthetic Technologies, together we are redefining the future of aesthetic medicine, leveraging our expertise in product design.'
The EON Laser introduces revolutionary technology in subcutaneous fat reduction, offering patients the industry's first touch-free and painless treatment option, delivering safer outcomes and eliminating recovery time. Utilizing laser energy, the EON Laser locally raises the temperature of subcutaneous fat, triggering lipolysis (the breakdown and metabolization of adipose tissue) while simultaneously cooling the skin, offering patients a pain-free alternative with unprecedented results. The scientifically proven EON Laser has received multiple FDA clearances and can be found at esthetic surgery centers and med-spas across the United States, offering patients a non-invasive alternative to liposuction and other surgical interventions.
'It's such a wonderful surprise to learn that EON has be recognized for its beautiful design,' said Janet Campbell, founder and Chairman of the Board, Dominion Aesthetic Technologies. 'It couldn't have been possible without the support of Intelligent Product Solutions. We are excited about the future of EON delivering the first of its kind non-invasive robotic fat reduction treatments. EON is dedicated to providing incredible patient outcomes with the safest fat reducing treatment available.'
About Intelligent Product Solutions
Intelligent Product Solutions (IPS), a subsidiary of Forward Industries (NASDAQ: FORD), is an award-winning global product design and development company with headquarters in New York. IPS offers a full range of expert product design and engineering services, with an expertise in medtech and wearable technology solutions. Its clients are among the leading brands in consumer electronics and medical devices, including Neuvotion, Google, Verizon, Zebra Technologies and Steinway. To learn more about IPS, visit https://intelligentproduct.solutions or contact info@ips-yes.com. Visit IPS on social media:https://www.linkedin.com/company/intelligent-product-solutions/
For more media information, contact:Lisa Hendrickson, LCH Communications for IPSLisa@lchcommunications.com516-643-1642
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/658ffae2-c750-4b47-adef-8c928e2c65fcSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
43 minutes ago
- Business Wire
HIMS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers' top executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Yaghsizian v. Hims & Hers Health, Inc., No. 25-cv-05321 (N.D. Cal.). If you suffered substantial losses and wish to serve as lead plaintiff of the Hims & Hers class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ CASE ALLEGATIONS: Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products. According to the complaint, on April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk A/S, starting with the immediate sale of 'a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform.' The Hims & Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Hims & Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk'; and (ii) as a result, there was a substantial risk that Hims & Hers' collaboration with Novo Nordisk would be terminated. The Hims & Hers class action lawsuit further alleges that on June 23, 2025, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims & Hers 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk.' On this news, the price of Hims & Hers stock fell more than 34%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Hims & Hers securities during the Class Period to seek appointment as lead plaintiff in the Hims & Hers class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Hims & Hers class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Hims & Hers class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Hims & Hers class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Forbes
3 hours ago
- Forbes
A Compound Made From Shrimp Shells Can Rid The Body Of Microplastics
For those unaware of the extent of the problem, microplastics (MPs) are said to be in essentially every person in every part of the world. Ice samples from the poles and tissue samples from the penis show the extent of penetration. Given that these pieces of plastic have been found in placenta samples and reproductive organs, we can say that children are being subjected to plastic exposure from birth. To what degree these nano and microplastics will hurt humans is still debated and research is ongoing, and the FDA states that they'll take regulatory action when adverse effects are known. However, the reason that people prefer to avoid becoming plasticized is the conventional wisdom that having small pieces of plastic within our immune cells, nerve cells, and altering which genes are expressed is something we'd want to avoid. There's certainly no known benefit. Microplastics have ben detected basically everywhere, including the brain and penis. Recent studies discuss the 'ubiquitous' extent of microplastics and their varied effects. Kidney death, liver inflammation, oxidative stress, cellular toxicity, alterations in gene expression and changes to the DNA itself are some of the observed effects of microplastic exposure. I will hypothesize that there's potentially a link between nanoplastics and mental wellbeing. Not just from the obvious observation that plastics in the brain are bad, although this is true; I instead refer to the interference that our gastrointestinal microbiota are suffering with their extracellular vesicles because of microplastics. Understanding the brain-gut-microbe axis and the effect that our intestinal flora there have an impact on our neurological function, one may observe that altering this intestinal environment with nanoplastics can have an effect on mental wellbeing. If you do start depressed, try milk aromatherapy. It shows promise in rats depressed because of gut-brain issues. The Dentist For those of us who don't enjoy visits to the dentist, we have reasons to be validated. Different materials are used in different dental practices, but a lot of them are plastic or packaged in plastic. By the nature of installing implants that will be subjected to the wear and tear of using one's mouth in daily life, microplastics are created and ingested. Other procedures like polishing restorations, ceramic crowns, using elastics, orthodontic appliances, and so on can generate particles. Think about the plastic fibers on the plastic toothbrush you grind against your teeth twice a day. Should we go back to chewing spruce sap? Remedies Chitin is a compound found in mushrooms and the exoskeletons of crustaceans and insects. Chitosan is easily made from chitin. It's used as a dietary supplement and sold to help consumers feel full, block fat absorption and lower cholesterol. Good for wound care as well. We ought to produce more of it and make it mainstream because we have another important reason to like it. A new study has shown that it can benefit our well-being in a novel and needed way: ridding our bodies of microplastics. The study was short but revealing, and I hope it will be reproduced with longer durations and human subjects. The researchers share two important conclusions. For even short periods of ingestion, microplastics accrue in the digestive tract, primarily the cecum which is the pouch between the small intestine and colon. Assuming that chemicals can leach from these plastics and that the particles themselves will eventually absorb into the wider body, it's clearly advantageous to expel this poison before it accrues/accumulates. The group of rats that was fed a diet supplemented with chitosan expelled more MPs that any of the other groups. Intriguingly and encouragingly for me, over a few days the rats released more MPs than they took in. This suggests that chitosan won't just block absorption of current MPs, but in fact facilitate the cleansing of the colon of recently ingested microplastics. Further, after the rats were euthanized and dissected, the chitosan group had the lightest colons which suggests that they had the least total waste accumulated. As side effects for adding chitosan to one's diet are minimal beyond some stomach upset, UNLESS YOU ARE ALLERGIC TO SHELLFISH OR MUSHROOMS, it seems like a reasonable addition. This is not medical advice and as I said, I look forward to studies done with humans for longer periods to provide us with more information. With said I'm intrigued. Singapore. Green buildings trap microplastics, clean the air and water, and cool the city. Prevention A better way to go than solving a problem is to prevent it. Microplastics come from plastics, and despite some laws and public initiatives, the industry is vital and won't fade away naturally. Proactive investment in alternatives will bring about a whole society shift; personal choice is not an option here. Plastic is ubiquitous and a consumer doesn't have a real option to move away from it. Our tap water and the air we breathe are contaminated, so we must do more than avoid microwaving food in plastic containers, or stop buying items packaged in plastic. If anyone has been to any store ever, they would know that this is impossible. Everything is wrapped in plastic. To exist in the modern world is to be a creator of waste; even the well-intentioned can do little more than be frustrated. Green roofs are 97.5% effective in removing microplastics. They're generally good for retaining storm water, cleaning the air and runoff, which lessens the work of wastewater treatment plants. Green roofs can contribute to an urban cooling effect, countering the Urban Head Island (UHI) problem. Singapore has been a prime example of this for years. Now, we find another reason to widely adopt the practice in every city, immediately. Singapore exemplifies greening a city to everyone's benefit. Great Pacific Garbage Patch Removing what's already been released is a net benefit. When considering the scale of the undertaking to clean the North Pacific Garbage Patch and the greenhouse gasses that will be released or the marine life that will be interfered with, it isn't immediately clear what the best approach might be. Leaving it and hoping a reef grows on top of it could make sense, given the rubber tire reef projects we've all heard about. A comparative analysis of the Ocean Cleanup shows that while there will be some impact from action, the effect of doing nothing is significantly worse. Proactive action where possible to remove what's been released before it continues to break down into microplastics and nano plastics is a viable strategy for long term environmental health. In the scenario presented, plastic pollution levels drop to below what's considered a safe limit. Inaction has the higher cost. Leaving plastics in the oceans will be more damaging than removal. Complex problems can't be solved with simple solutions. Plastics can't be completely replaced, but we can adapt the ways we use them and consider novel strategies to mitigate their harm. When these strategies prove themselves to be effective, they ought to be systematically applied.
Yahoo
7 hours ago
- Yahoo
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
Gilead Sciences, Inc. GILD announced that the FDA has placed a clinical hold on studies on pipeline candidates, GS-1720 and/or GS-4182, for the treatment of HIV. GS-1720 is an investigational integrase strand transfer inhibitor and/or GS-4182 is an investigational capsid inhibitor. Shares were down 2.6% on the news. Year to date, shares of GILD have gained 20% against the industry's decline of 0.5%. Image Source: Zacks Investment Research The FDA placed a clinical hold on the studies due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182. The studies that have been placed on hold are a phase II/III study evaluating the safety and efficacy of oral weekly regimen of GS-1720 in combination with GS-4182 versus Biktarvy in virologically suppressed people with HIV-1 and a phase II/III study evaluating the safety and efficacy of oral weekly regimen of GS-1720 in combination with GS-4182 versus Biktarvy in treatment-naive people with HIV-1. Three additional phase I studies of either these candidates/or their combinations are also on hold. While the clinical hold will somewhat derail the development program for these candidates, GILD is a market leader in HIV treatments. Gilead's flagship drug, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg, BIC/FTC/TAF), for HIV-1 infection has become the leading prescribed regimen for both treatment-naïve and switch patients. Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum for GILD in the upcoming quarters. Descovy (FTC 200 mg/TAF 25 mg) for pre-exposure prophylaxis (PrEP) is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States. Gilead's efforts to innovate its HIV portfolio are impressive. Late-stage studies, PURPOSE 1 and PURPOSE 2, validated lenacapavir's potential to prevent HIV. The FDA accepted new drug application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a target action date of June 19, 2025. Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote The European Medicines Agency validated the Marketing Authorization Application and EU-Medicines for All application for twice-yearly lenacapavir for HIV prevention. The successful development and potential approval of lenacapavir for the prevention of the disease should solidify Gilead's HIV franchise. Per GILD, lenacapavir, with its twice-yearly dosing, could set a new bar for HIV prevention and allow PrEP to reach out to a larger number of people who could benefit from a prevention regimen. However, Biktarvy sales are expected to be under pressure due to Medicare Part D redesign, which, in turn, should affect overall HIV growth. Gilead's faces stiff competition from GSK plc GSK in the HIV space. GSK's HIV portfolio sales are being driven by strong patient demand for Cabenuva, Apretude and Dovato. The company is also focused on the development of the next generation of HIV innovation with integrase inhibitors (INSTIs) for HIV treatment and prevention. Gilead currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Bayer BAYRY, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate Novartis' 2025 earnings per share (EPS) has risen from $8.46 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 35 cents to $9.02 during this timeframe. The stock has risen 24.7% so far this year. BAYRY's 2025 EPS estimate has increased from $1.19 to $1.25 for 2025 over the past 60 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe. Year to date, shares of Bayer have surged 56.7%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
